Once- vs Twice-Weekly Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Blood Adv 2024 Jul 18;[EPub Ahead of Print], MA Dimopoulos, D Coriu, S Delimpasi, I Spicka, TE Upchurch, B Fang, R Talpur, EA Faber, M Beksac, X LeleuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.